Is the daytime use of trazodone for agitation in elderly patients with Alzheimer’s disease or other dementias a recognized standard of practice and appropriate for a psychiatric prescriber?

Daytime Trazodone for Agitation in Dementia: Not Standard Practice

Trazodone is NOT a recognized standard of practice for daytime agitation management in elderly patients with Alzheimer's disease or dementia, and its use for this indication lacks robust supporting evidence. While trazodone is FDA-approved only for major depressive disorder in adults 1, it is being used off-label in clinical practice for behavioral symptoms in dementia, but this represents common practice rather than evidence-based standard care.

The Evidence Gap

The most recent 2025 geriatric emergency department guidelines 2 examining medications for severe agitation in older adults did not include trazodone in their systematic review. These guidelines evaluated haloperidol, droperidol, lorazepam, midazolam, olanzapine, quetiapine, and ziprasidone—but notably, trazodone was absent from the evidence base for acute agitation management. This is telling: if trazodone were a recognized standard, it would have been included in this comprehensive 2025 guideline review.

What the Research Actually Shows

The evidence for trazodone in dementia-related agitation is weak and contradictory:

• A 2004 Cochrane review 3 concluded there is "insufficient evidence to recommend the use of trazodone" for behavioral manifestations of dementia, noting that longer-term trials with larger samples are needed.

• The landmark 2000 multicenter trial 4 found no significant differences between trazodone (mean dose 200 mg/day), haloperidol, behavioral management techniques, or placebo for agitation in AD. Only 34% of subjects improved overall, with comparable modest reductions across all groups.

• A 2001 study 5 suggested trazodone may help when mild depressive symptoms coexist with agitation, but this represents a specific subpopulation rather than general agitation management.

• Recent 2024-2026 observational data 6, 7, 8 shows trazodone is widely used in clinical practice for agitation, insomnia, and behavioral symptoms, but these studies acknowledge the evidence base remains limited and do not establish it as standard practice.

Critical Safety Concerns

The FDA label 1 highlights significant risks particularly relevant to elderly dementia patients:

• Orthostatic hypotension leading to falls (reported in 30% of elderly users in one study 6)
• QT prolongation with risk of ventricular arrhythmias
• Sedation and drowsiness increasing fall risk
• Not studied in elderly populations with dementia specifically
• Should be used with caution in geriatric patients per FDA guidance 1

What IS Recommended

The 2025 guidelines 2 emphasize:

• Nonpharmacologic approaches are always preferred first-line (person-centered communication, sensory therapy, environmental modifications)
• When medications are necessary for severe agitation, oral quetiapine had the best safety profile (OR 0.27 for adverse events compared to haloperidol)
• Benzodiazepines should be avoided (midazolam had 53% adverse event rate)
• Use lowest effective doses and oral formulations when possible

The 2014 multidisciplinary expert panel 9 reinforced that nonpharmacologic strategies are the preferred first-line approach except in emergency situations, and that psychotropics should only be used after systematic assessment of underlying causes.

Clinical Bottom Line

For a psychiatric prescriber, using daytime trazodone for agitation in dementia is not inappropriate per se, but it is not evidence-based standard practice. The practice appears to be driven by:

1. Familiarity and perceived safety compared to antipsychotics
2. Off-label use based on clinical experience rather than robust evidence
3. Desire to avoid antipsychotics given their black box warnings in dementia

A more evidence-based approach would be:

• First: Implement nonpharmacologic interventions and identify/address triggers
• If medication needed: Consider low-dose oral quetiapine (best safety profile in 2025 data 2)
• If depression coexists: Consider citalopram or agomelatine 7
• Reserve trazodone for: Nighttime sleep disturbances (where it has better evidence 10) or when agitation occurs with comorbid depression 5

Important Caveats

• Trazodone may have emerging neuroprotective properties through UPR modulation 10, 11, but this remains investigational
• The 2026 consensus 7 notes that when safety is prioritized, selected antidepressants including citalopram may be preferred over antipsychotics
• Any pharmacological treatment should be time-limited, not routine or long-term 7
• Falls are a major concern—30% incidence reported 6—making daytime use particularly problematic in ambulatory elderly patients

This is not a "new" standard—it's an old practice that persists despite limited evidence. If you're seeing increased use, it likely reflects local prescribing culture rather than emerging evidence-based guidelines.